scispace - formally typeset
K

Koen Augustyns

Researcher at University of Antwerp

Publications -  227
Citations -  6882

Koen Augustyns is an academic researcher from University of Antwerp. The author has contributed to research in topics: Dipeptidyl peptidase & Proteases. The author has an hindex of 43, co-authored 214 publications receiving 5849 citations. Previous affiliations of Koen Augustyns include Rega Institute for Medical Research & Fox Chase Cancer Center.

Papers
More filters
Journal ArticleDOI

Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family

TL;DR: The steady-state catalytic parameters for a relevant selection of chemokines previously reported to alter their chemotactic behavior due to CD26/dipeptidyl peptidase IV-catalyzed truncation are determined and reveal a striking selectivity for stromal cell-derived factor-1α (CXCL12) and macrophage-derived chemokine (CCL22).
Journal ArticleDOI

Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)

TL;DR: In this paper, the authors explored the structure-activity relationship around the core scaffold of the N-4-quinolinoyl-gly-(2S)-cyanoPro scaffold and reported extensively optimized compounds that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, and prolyl oligopeptidase (PREP).
Journal ArticleDOI

In vitro antioxidant profile of phenolic acid derivatives.

TL;DR: Several caffeic acid esters isolated from propolis exhibit interesting antioxidant properties, but their in vivo use is compromised by hydrolysis of the ester bond in the gastrointestinal tract, so their in vitro antioxidant profile was determined.
Journal ArticleDOI

When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157.

TL;DR: These results not only report on new and very potent RIPK1 inhibitors but also highlight the risk of misinterpretation when using these two PERK inhibitors in the context of ER stress, cell death and inflammation.